EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische StudieOpen Access

Twice-Daily Dolutegravir–Based Antiretroviral Therapy With 1 Month of Daily Rifapentine and Isoniazid for Tuberculosis Prevention

Anthony T Podany iD, Yoninah Cramer, Marjorie Imperial, Susan L Rosenkranz, Anchalee Avihingsanon, Roberto Arduino, Wadzanai Samaneka, Irina Gelmanova, Rada Savic, Susan Swindells iD, Rodney Dawson, Anne F Luetkemeyer

Clinical Infectious Diseases · 2024

DOI: 10.1093/cid/ciae183 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Anthony T Podany und 11 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, University of Nebraska Medical Center, Omaha. Hauptthemen laut MEDLINE: Pyridones, Heterocyclic Compounds, 3-Ring, Piperazines, Oxazines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

One month of daily rifapentine + isoniazid (1HP) is an effective, ultrashort option for tuberculosis prevention in people with human immunodeficiency virus (HIV). However, rifapentine may decrease antiretroviral drug concentrations and increase the risk of virologic failure. AIDS Clinical Trials Group A5372 evaluated the effect of 1HP on the pharmacokinetics of twice-daily dolutegravir.

Methods

A5372 was a multicenter, pharmacokinetic study in people with HIV (≥18 years) already on dolutegravir-containing antiretroviral therapy with HIV RNA <50 copies/mL. Participants received daily rifapentine/isoniazid (600 mg/300 mg) for 28 days as part of 1HP. Dolutegravir was increased to 50 mg twice daily during 1HP, and intensive pharmacokinetic sampling was performed on day 0 (before 1HP) and on the final day of 1HP treatment.

Results

Thirty-two participants (41% female; 66% Black/African; median [Q1, Q3] age, 42 [34, 49] years) were included in the pharmacokinetic analysis; 31 had HIV RNA <50 copies/mL at the end of 1HP dosing. One participant had an HIV RNA of 160 copies/mL at day 28, with HIV RNA <50 copies/mL upon repeat testing on day 42. The median (Q1, Q3) dolutegravir trough concentration was 1751 ng/mL (1195, 2542) on day 0 versus 1987 ng/mL (1331, 2278) on day 28 (day 28:day 0 geometric mean ratio, 1.05 [90% confidence interval, .93–1.2]; P = .43). No serious adverse events were reported.

Conclusions

Dolutegravir trough concentrations with 50 mg twice-daily dosing during 1HP treatment were greater than those with standard-dose dolutegravir once daily without 1HP. These pharmacokinetic, virologic, and safety data provide support for twice-daily dolutegravir use in combination with 1HP for tuberculosis prevention. Clinical Trials Registration NCT04272242.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyridonesHeterocyclic Compounds, 3-RingPiperazinesOxazinesRifampinIsoniazidHIV InfectionsTuberculosisHumansFemaleAdultMaleMiddle AgedAntitubercular AgentsDrug Administration ScheduleAnti-HIV AgentsDrug Therapy, CombinationDolutegravir

Stichwörter der Autor:innen

HIV/AIDSpharmacodynamicspharmacokineticsrifapentinetuberculosis

Substanzen

PyridonesHeterocyclic Compounds, 3-RingPiperazinesOxazinesRifampinIsoniazidAntitubercular AgentsAnti-HIV AgentsDolutegravirrifapentine

Autor:innen und Institutionen

  • College of Pharmacy, University of Nebraska Medical Center, Omaha.
  • Statistical and Data Analysis Center, Harvard School of Public Health, Boston, Massachusetts.
  • College of Pharmacy, University of California, San Francisco.
  • Thai Red Cross AIDS Research Center and Center of Excellence in Tuberculosis, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • McGovern Medical School, University of Texas Health Science Center at Houston, Texas.
  • College of Health Sciences, University of Zimbabwe, Harare.

ORCID-Profile: Anthony T Podany, Susan Swindells

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Podany, A. T., Cramer, Y., Imperial, M., Rosenkranz, S. L., Avihingsanon, A., Arduino, R., Samaneka, W., Gelmanova, I., Savic, R., Swindells, S., Dawson, R., & Luetkemeyer, A. F. (2024). Twice-Daily Dolutegravir–Based Antiretroviral Therapy With 1 Month of Daily Rifapentine and Isoniazid for Tuberculosis Prevention. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae183

Vancouver

Podany AT, Cramer Y, Imperial M, Rosenkranz SL, Avihingsanon A, Arduino R, et al. Twice-Daily Dolutegravir–Based Antiretroviral Therapy With 1 Month of Daily Rifapentine and Isoniazid for Tuberculosis Prevention. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciae183

BibTeX
@article{Podany2024,
  author = {Podany, Anthony T and Cramer, Yoninah and Imperial, Marjorie and Rosenkranz, Susan L and Avihingsanon, Anchalee and Arduino, Roberto and Samaneka, Wadzanai and Gelmanova, Irina and Savic, Rada and Swindells, Susan and Dawson, Rodney and Luetkemeyer, Anne F},
  title = {Twice-Daily Dolutegravir–Based Antiretroviral Therapy With 1 Month of Daily Rifapentine and Isoniazid for Tuberculosis Prevention},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  doi = {10.1093/cid/ciae183}
}
Kostenlos starten →